Additional file 1: of Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial

Laura Collett, Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Adrian Bloor(The Christie NHS Foundation Trust), David Allsup(University of Leeds), Lucy McParland, Jamie B. Oughton, Dena Howard(University of Leeds), Claire Dimbleby, Anna Hockaday(University of Leeds), David H. Phillips, Andy Rawstron, Claire Hulme(University of Leeds), Kathryn McMahon, Talha Munir(Leeds Teaching Hospitals NHS Trust)
Figshare
January 1, 2017
10.6084/m9.figshare.5335669.v1
Cited by 0

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k